JP2007521835A - ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法 - Google Patents

ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法 Download PDF

Info

Publication number
JP2007521835A
JP2007521835A JP2006553250A JP2006553250A JP2007521835A JP 2007521835 A JP2007521835 A JP 2007521835A JP 2006553250 A JP2006553250 A JP 2006553250A JP 2006553250 A JP2006553250 A JP 2006553250A JP 2007521835 A JP2007521835 A JP 2007521835A
Authority
JP
Japan
Prior art keywords
nicotinamide riboside
cell
nrk
prodrug
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006553250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007521835A5 (enExample
Inventor
ブレンナー，チャールズ，エム．
ビーガノウスキー，パウエル
Original Assignee
トラスティーズ・オブ・ダートマウス・カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34860407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007521835(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by トラスティーズ・オブ・ダートマウス・カレッジ filed Critical トラスティーズ・オブ・ダートマウス・カレッジ
Publication of JP2007521835A publication Critical patent/JP2007521835A/ja
Publication of JP2007521835A5 publication Critical patent/JP2007521835A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2006553250A 2004-02-10 2005-02-09 ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法 Pending JP2007521835A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54334704P 2004-02-10 2004-02-10
PCT/US2005/004337 WO2005077091A2 (en) 2004-02-10 2005-02-09 Nicotinamide riboside kinase compositions and methods for using the same

Publications (2)

Publication Number Publication Date
JP2007521835A true JP2007521835A (ja) 2007-08-09
JP2007521835A5 JP2007521835A5 (enExample) 2008-05-22

Family

ID=34860407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006553250A Pending JP2007521835A (ja) 2004-02-10 2005-02-09 ニコチンアミドリボシドキナーゼ組成物およびそれらの使用方法

Country Status (6)

Country Link
US (3) US8197807B2 (enExample)
EP (1) EP1723227A4 (enExample)
JP (1) JP2007521835A (enExample)
AU (1) AU2005211773B2 (enExample)
CA (1) CA2555675A1 (enExample)
WO (1) WO2005077091A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538923A (ja) * 2005-04-25 2008-11-13 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびその組成物を使用するための方法

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114626B2 (en) * 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
EP3006040B1 (en) * 2004-06-04 2017-11-22 Washington University Methods and compositions for treating neuropathies
US20060229265A1 (en) * 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
EP2124985A4 (en) * 2007-01-26 2011-06-08 Univ Washington METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
CA2928656C (en) 2013-10-30 2020-07-28 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
CN106715455A (zh) 2014-06-06 2017-05-24 葛兰素史密斯克莱知识产权（第2 号）有限公司 烟酰胺核苷类似物及其药物组合物和用途
CA2956163C (en) 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
WO2016144660A1 (en) 2015-03-09 2016-09-15 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
EP3271370B1 (en) 2015-03-16 2023-06-21 Chromadex Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
EP3288530A1 (en) * 2015-05-01 2018-03-07 The Procter and Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
CA3010730C (en) 2016-01-11 2021-02-16 The Procter & Gamble Company Method of treating a skin condition and compositions therefor
AU2017232930B2 (en) 2016-03-16 2021-03-25 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
CA3021571C (en) 2016-04-20 2023-01-03 ChromaDex Inc. Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
JP7136795B2 (ja) 2016-11-29 2022-09-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 母体の健康および／または子の健康を向上させるためのｎａｄ前駆体の使用
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
US10660838B2 (en) 2017-06-23 2020-05-26 The Procter & Gamble Company Composition and method for improving the appearance of skin
US11414407B2 (en) 2017-12-22 2022-08-16 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
EP3817717A1 (en) 2018-07-03 2021-05-12 The Procter & Gamble Company Method of treating a skin condition
CA3110296A1 (en) 2018-09-27 2020-04-02 Societe Des Produits Nestle S.A. Compositions and methods using at least one glycine or derivative thereof, at least one n-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or nad+ precursor
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
US20220290122A1 (en) * 2019-02-19 2022-09-15 Whitehead Institute For Biomedical Research Methods and agents for modulating mitochondrial nad levels
US20220125814A1 (en) * 2019-03-21 2022-04-28 Fred Hutchinson Cancer Research Center Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor
US20220168271A1 (en) * 2019-03-29 2022-06-02 Societe Des Produits Nestle S.A. Compositions and methods for increasing t cell function
EP3986420A1 (en) 2019-06-18 2022-04-27 Mitopower LLC Nicotinyl riboside compounds and their uses
CN110412157A (zh) * 2019-07-17 2019-11-05 广州金评检测研究院有限公司 一种烟酰胺原料中烟酸的测定方法
IL289941B2 (en) 2019-07-19 2025-07-01 Biosynth Ag Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
CA3166897A1 (en) 2020-04-01 2021-10-07 Societe Des Produits Nestle S.A. Compositions and methods containing n-acetylcystein and nicotinamide riboside for prevention and treatment of neurological diseases and conditions
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
WO2021247496A1 (en) 2020-06-01 2021-12-09 The Procter & Gamble Company Method of improving penetration of a vitamin b3 compound into skin
US20240009219A1 (en) 2020-11-18 2024-01-11 Societe Des Produits Nestle S.A. Compositions and methods using a combination of oleuropein and nicotinamide riboside for cellular energy
CN112553178B (zh) * 2020-12-25 2023-03-10 中山俊凯生物技术开发有限公司 热稳定性和活性增强的烟酰胺核糖激酶突变体及其编码基因和应用
EP4401721A4 (en) 2021-10-17 2025-10-15 Univ Of South Alabama Foundation For Research And Commercialization CANCER TREATMENT
LT7046B (lt) 2022-04-15 2024-02-12 Vilniaus Universitetas Hidrolazės ir jų panaudojimas
CN115896062B (zh) * 2022-08-10 2024-10-01 福建师范大学 一种烟酰胺核糖苷激酶突变体及其相关产品和应用
LT7066B (lt) 2023-11-17 2024-06-25 Vilimas Vladas Didelės talpos medžio sulos atitirpinimo būdas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030175925A1 (en) * 2001-02-27 2003-09-18 Oleg Kurnasov Nicotinamide ribonucleoside kinase
JP2003530079A (ja) * 1999-11-04 2003-10-14 インサイト・ゲノミックス・インコーポレイテッド ヒトトランスフェラーゼ分子

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1995013392A1 (en) 1993-11-09 1995-05-18 Medical College Of Ohio Stable cell lines capable of expressing the adeno-associated virus replication gene
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5623054A (en) 1994-06-23 1997-04-22 The General Hospital Corporation Crucifer AFT proteins and uses thereof
EP0796339A1 (en) 1994-12-06 1997-09-24 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
ES2150832B1 (es) 1996-06-12 2001-06-16 Fichtel & Sachs Ag Dispositivo de maniobra para la maniobra, en particular maniobra neumatica, de un embrague de friccion.
AU5603998A (en) 1996-12-18 1998-07-15 Targeted Genetics Corporation Recombinase-activatable AAV packaging cassettes for use in the production of AV vectors
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
WO1999061643A1 (en) 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1588163A2 (en) * 2003-01-23 2005-10-26 Eirx Therapeutics Ltd Kinases and gpcrs involved in apoptosis
WO2005077344A2 (en) * 2003-08-29 2005-08-25 The Brigham And Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530079A (ja) * 1999-11-04 2003-10-14 インサイト・ゲノミックス・インコーポレイテッド ヒトトランスフェラーゼ分子
US20030175925A1 (en) * 2001-02-27 2003-09-18 Oleg Kurnasov Nicotinamide ribonucleoside kinase

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538923A (ja) * 2005-04-25 2008-11-13 トラスティーズ・オブ・ダートマウス・カレッジ ニコチンアミドリボシドキナーゼ組成物およびその組成物を使用するための方法

Also Published As

Publication number Publication date
EP1723227A2 (en) 2006-11-22
US8383086B2 (en) 2013-02-26
US20120251463A1 (en) 2012-10-04
US8197807B2 (en) 2012-06-12
AU2005211773A1 (en) 2005-08-25
US20070027095A1 (en) 2007-02-01
WO2005077091A8 (en) 2006-09-14
US20080206221A1 (en) 2008-08-28
CA2555675A1 (en) 2005-08-25
WO2005077091A3 (en) 2005-12-22
AU2005211773B2 (en) 2009-06-25
WO2005077091A2 (en) 2005-08-25
EP1723227A4 (en) 2007-09-19

Similar Documents

Publication Publication Date Title
US8383086B2 (en) Nicotinamide riboside kinase compositions and methods for using the same
CA2609633C (en) Nicotinamide riboside compositions
US5906819A (en) Rho target protein Rho-kinase
JP3193301B2 (ja) 生理活性タンパク質ｐ１６０
ES2284502T3 (es) 22025, una nueva nucleotido ciclico fosfodiesterasa humana.
CA2270910A1 (en) Glutathione s-transferase (gst) genes in cancer
WO1998021359A9 (en) Glutathione s-transferase (gst) genes in cancer
Yabu et al. A novel mitochondrial sphingomyelinase in zebrafish cells
Chauhan et al. Glyoxalase I gene deletion mutants of Leishmania donovani exhibit reduced methylglyoxal detoxification
CA2568201C (en) Identification of ergothioneine transporter and therapeutic uses thereof
US20040242461A1 (en) Modulators of telomere stability
US20040180845A1 (en) Methods and compositions for modulating glycogen synthesis and breakdown
US20030092116A1 (en) Novel nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and ATPase-like molecules and uses therefor
US20030130485A1 (en) Novel human genes and methods of use thereof
KR20030011868A (ko) 신규 효소 유전자 및 그의 발현 생산물
US20050014692A1 (en) Lactate dehydrogenase as a novel target and reagent for diabetes therapy
Belužić et al. S-Adenosylhomocysteine hydrolase (AHCY) deficiency: a natural model system for methylation research
Acton Acid Anhydride Hydrolases: Advances in Research and Application: 2011 Edition: ScholarlyPaper
Eberhard GENETIC KNOCKOUT OF CREATINE KINASE BRAIN-TYPE IMPAIRS DRUG METABOLISM AND COGNITIVE FUNCTION IN MICE
JP4476805B2 (ja) 精製ＰＫＢＳｅｒ４７３キナーゼおよびその用途
JP4674332B2 (ja) Ｔｘｋ複合体およびその利用
JPWO2006070804A1 (ja) テロメレース活性阻害方法および阻害剤
JP2005516608A (ja) エネルギー恒常性の調節に関与するキナーゼ
KALDOR actomyosin of aging rats1, 2
Yalowitz Identification and characterization of a family of nicotinamide 5'-mononucleotide adenylyltransferases from yeast and humans

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110719